Dyne Therapeutics expands Hercules Capital debt facility to up to $400M
What's the deal? Dyne Therapeutics, a clinical-stage biotech focused on rare neuromuscular diseases, has expanded its non-dilutive debt facility with Hercules CapitalDealroom has a profile for this one. Try Dealroom → to up to $400M. The amendment, announced on June 17, 2026, added up to $125M in additional borrowing capacity, with $50M funded at closing.
Including that $50M, Dyne has now borrowed $200M in total across three tranches and maintains access to up to $200M in potential future funding. The remaining tranches are tied to milestone achievements or Hercules' discretion.
"This additional access to capital enhances our financial flexibility as we prepare for two potential U.S. launches in the next two years," said Erick LuceraDealroom has a profile for this one. Try Dealroom →, Dyne's chief financial officer.
Why now? Dyne is approaching critical regulatory milestones for two lead drug candidates: z-rostudirsen for Duchenne muscular dystrophy (DMD) and z-basivarsen for myotonic dystrophy type 1 (DM1). Both could launch in the US by 2028, requiring significant capital for commercialisation.
The debt structure is non-dilutive, meaning it avoids diluting existing shareholders — an important consideration for a publicly traded company (NASDAQ: DYN) gearing up for the expensive transition from clinical-stage to commercial operations.
What could go wrong? Neither drug has received regulatory approval yet. Clinical setbacks or delays could leave Dyne servicing a large debt load without the revenue to support it. The milestone-based structure of the remaining tranches mitigates some risk for both sides, but the $200M already drawn represents a substantial obligation for a pre-revenue company.
The signal: Hercules Capital's willingness to extend up to $400M in non-dilutive debt to a pre-revenue biotech underscores the growing appetite among specialty lenders to back late-stage life sciences companies approaching commercialisation. For Dyne Therapeutics, which Dealroom classifies as late stage, the structured facility offers a way to fund two potential US drug launches without further diluting public shareholders — a playbook likely to be replicated as more clinical-stage biotechs seek alternatives to equity financing during capital-intensive regulatory transitions.
Read more: Benzinga
